Assessment of Amprenavir plasma Cmin levels in patients receiving once-daily fos-amprenavir in combination with either 100 or 200 mg ritonavir

被引：0
|
作者：
Muret, P.
Muret, P.
Montange, D.
Bettinger, D.
Faller, J. P.
Beck-Wirth, G.
Martha, B.
Hoen, B.
机构：
来源：
FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2007年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
216
引用
收藏
页码：44 / 44
页数：1
相关论文
共 27 条
  • [1] A real life six months pharmacokinetic/pharmacodynamic study of amprenavir in patients receiving once-daily fosamprenavir in combination with either 100 or 200 mg ritonavir
    Muret, Patrice
    Montange, Damien
    Bettinger, Dominique
    Drobacheff, Christine
    Faller, Jean-Pierre
    Beck-Wirth, Genevieve
    Hoen, Bruno
    THERAPEUTIC DRUG MONITORING, 2007, 29 (04) : 541 - 542
  • [2] Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers
    Ruane, Peter J.
    Luber, Andrew D.
    Wire, Mary Beth
    Lou, Yu
    Shelton, Mark J.
    Lancaster, C. Tracey
    Pappa, Keith A.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (02) : 560 - 565
  • [3] Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients
    Nadler, JP
    Gathe, JC
    Pollard, RB
    Richmond, GJ
    Liao, QM
    Griffith, S
    Lancaster, CT
    Hernandez, JE
    Pappa, KA
    BMC INFECTIOUS DISEASES, 2003, 3 (1)
  • [4] Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients
    Jeffrey P Nadler
    Joseph C Gathe
    Richard B Pollard
    Gary J Richmond
    Qiming Liao
    Sandy Griffith
    C Tracey Lancaster
    Jaime E Hernandez
    Keith A Pappa
    BMC Infectious Diseases, 3
  • [5] High rate of gastrointestinal side effects in patients treated with amprenavir, lopinavir and ritonavir (200 mg twice daily)
    Mauss, S
    Scholten, S
    Wolf, E
    Berger, F
    Schmutz, G
    Postel, E
    Rockstroh, JK
    ANTIVIRAL THERAPY, 2002, 7 (03) : L61 - L61
  • [6] Comparison of Once-Daily Fosamprenavir Boosted with Either 100 or 200 mg of Ritonavir, in Combination with Abacavir/Lamivudine: 96-Week Results from COL100758
    Hicks, Charles B.
    DeJesus, Edwin
    Sloan, Louis M.
    Sension, Michael G.
    Wohl, David A.
    Liao, Qiming
    Ross, Lisa L.
    Pakes, Gary E.
    Pappa, Keith A.
    Lancaster, C. Tracey
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2009, 25 (04) : 395 - 403
  • [7] Steady-State Amprenavir, Tenofovir, and Emtricitabine Pharmacokinetics Before and After Reducing Ritonavir Boosting of a Fosamprenavir/Tenofovir/Emtricitabine Regimen from 200 mg to 100 mg Once Daily (TELEX II)
    Parks, David A.
    Jennings, H. Clay
    Taylor, Christopher
    Pakes, Gary E.
    Acosta, Edward P.
    HIV CLINICAL TRIALS, 2009, 10 (03): : 160 - 167
  • [8] Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily
    Autar, RS
    Ananworanich, J
    Apateerapong, W
    Sankote, J
    Hill, A
    Hirschel, B
    Cooper, D
    Lange, J
    Phanuphak, P
    Ruxrungtham, K
    Burger, D
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 54 (04) : 785 - 790
  • [9] Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients
    Ford, Jennifer
    Boffito, Marta
    Maitland, Desmond
    Hill, Andrew
    Back, David
    Khoo, Saye
    Nelson, Mark
    Moyle, Graeme
    Gazzard, Brian
    Pozniak, Anton
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 58 (05) : 1009 - 1016
  • [10] Pharmacokinetics, Efficacy, and Safety of Darunavir/Ritonavir 800/100 mg Once-Daily in Treatment-Naive and -Experienced Patients
    Boffito, Marta
    Miralles, Diego
    Hill, Andrew
    HIV CLINICAL TRIALS, 2008, 9 (06): : 418 - 427
123